RHHBF Quote, Financials, Valuation and Earnings

Addex Therapeutics has a net margin of -- compared to Roche Holding AG's net margin of -2841.85%. Roche Holding AG's return on equity of 32.32% beat Addex Therapeutics's return on equity of 91.08%.

Roche Holding AG has a consensus price target of --, signalling downside risk potential of -83.14%. On the other hand Addex Therapeutics has an analysts' consensus of -- which suggests that it could grow by 279.75%. Given that Addex Therapeutics has higher upside potential than Roche Holding AG, analysts believe Addex Therapeutics is more attractive than Roche Holding AG.

Roche Holding AG has a beta of 0.357, which suggesting that the stock is 64.298% less volatile than S&P 500. In comparison Addex Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Roche Holding AG has a quarterly dividend of $10.93 per share corresponding to a yield of 3.84%. Addex Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roche Holding AG pays 66.01% of its earnings as a dividend. Addex Therapeutics pays out -- of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Roche Holding AG quarterly revenues are --, which are smaller than Addex Therapeutics quarterly revenues of $62.3K. Roche Holding AG's net income of -- is lower than Addex Therapeutics's net income of -$1.8M. Notably, Roche Holding AG's price-to-earnings ratio is 19.28x while Addex Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 3.38x versus 14.60x for Addex Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

CRISPR Therapeutics AG has a net margin of -- compared to Roche Holding AG's net margin of --. Roche Holding AG's return on equity of 32.32% beat CRISPR Therapeutics AG's return on equity of --.

Roche Holding AG has a consensus price target of --, signalling downside risk potential of -83.14%. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $81.75 which suggests that it could grow by 100.76%. Given that CRISPR Therapeutics AG has higher upside potential than Roche Holding AG, analysts believe CRISPR Therapeutics AG is more attractive than Roche Holding AG.

Roche Holding AG has a beta of 0.357, which suggesting that the stock is 64.298% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.621, suggesting its more volatile than the S&P 500 by 62.069%.

Roche Holding AG has a quarterly dividend of $10.93 per share corresponding to a yield of 3.84%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roche Holding AG pays 66.01% of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Roche Holding AG quarterly revenues are --, which are smaller than CRISPR Therapeutics AG quarterly revenues of --. Roche Holding AG's net income of -- is lower than CRISPR Therapeutics AG's net income of -$85.9M. Notably, Roche Holding AG's price-to-earnings ratio is 19.28x while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 3.38x versus -- for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.

NLS Pharmaceutics has a net margin of -- compared to Roche Holding AG's net margin of --. Roche Holding AG's return on equity of 32.32% beat NLS Pharmaceutics's return on equity of --.

Roche Holding AG has a consensus price target of --, signalling downside risk potential of -83.14%. On the other hand NLS Pharmaceutics has an analysts' consensus of -- which suggests that it could grow by 12400.65%. Given that NLS Pharmaceutics has higher upside potential than Roche Holding AG, analysts believe NLS Pharmaceutics is more attractive than Roche Holding AG.

Roche Holding AG has a beta of 0.357, which suggesting that the stock is 64.298% less volatile than S&P 500. In comparison NLS Pharmaceutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Roche Holding AG has a quarterly dividend of $10.93 per share corresponding to a yield of 3.84%. NLS Pharmaceutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roche Holding AG pays 66.01% of its earnings as a dividend. NLS Pharmaceutics pays out -- of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Roche Holding AG quarterly revenues are --, which are smaller than NLS Pharmaceutics quarterly revenues of --. Roche Holding AG's net income of -- is lower than NLS Pharmaceutics's net income of --. Notably, Roche Holding AG's price-to-earnings ratio is 19.28x while NLS Pharmaceutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 3.38x versus -- for NLS Pharmaceutics. Usually stocks with elevated PS ratios are considered overvalued.